Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Infectious Disease
Is there any evidence that TNF inhibitors alter immunogenicity of vaccines?
If so, does delaying/skipping a dose improve immunogenicity?
Related Questions
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Do you have to extend treatment for acute Lyme disease if a patient is on high dose steroids for another indication?
What are your vaccine recommendations while patients are on biologics?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
Do you provide empiric doxycycline for Lyme Disease to asymptomatic patients after a tick bite who haven't developed Erythema migrans or are not sure it was an Ixodes tick?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?